SUNFLOWER(SZ:300111) Ju Chao Zi Xun·2025-09-08 09:16Group 1 - The company announced plans to acquire controlling stakes in Zhangzhou Xipu Material Technology Co., Ltd. and the remaining 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment, which is expected to constitute a major asset restructuring [1] - Since its transition to the pharmaceutical industry in 2019, the company has struggled to overcome operational difficulties, with a net profit of only 1.16 million yuan in the first half of 2024, a year-on-year decline of 36%, and a full-year net profit of approximately 7.8 million yuan in 2023, down 64% year-on-year [1] - The company is shifting its focus to the semiconductor materials sector, with Xipu Material aiming to become a primary supplier of electronic-grade materials, including hexafluorobutylene and trifluorine [1] Group 2 - The semiconductor materials industry has high technical barriers and long customer certification cycles, which can take 1 to 3 years, raising questions about the company's ability to successfully transition into this high-tech manufacturing field [2] - The company's historical performance has been characterized by a "high opening and low walking" trajectory, having previously been a leading enterprise in the photovoltaic sector before facing significant challenges and transitioning to the pharmaceutical industry [2] - Despite continuous declines in performance, the company's stock price has increased by over 53% this year, indicating market speculation regarding its transformation prospects [2] Group 3 - The transaction is still in the planning stage, with specific details regarding valuation and performance commitments yet to be disclosed, leaving the success of the acquisition uncertain [3]